

Bill for mandatory coverage of scalp cooling passed by Texas House committee

On Friday 16th April the bill, HB1588, proposing mandatory insurance coverage for FDA cleared scalp cooling costs for cancer patients, passed the Texas House committee on insurance with 8 votes to 1.

Paxman are proud to have actively supported these efforts along with a number of Key Opinion Leaders and former patients who have benefitted from the use of Paxman Scalp Cooling during their own cancer treatment. Members of Paxman's private closed Patient Facebook Support Group have also shown significant contribution and support of the bill. Dr. Julie Nangia, assistant professor in the Lester and Sue Smith Breast Center within the NCI-designated Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine, who was the Principal Investigator of the Scalp Cooling Alopecia Prevention trial (SCALP) - the first-ever randomized clinical trial to evaluate modern scalp cooling, as part of Paxman's FDA clearance process - supported the bill in person at the hearing on 30th March 2021. Rep. Jeff Leach introduced the bill along with joint authors: Rep. Victoria Neave, Rep. Justin Holland, Rep. Ken King and Rep. Kyle Kacal.

The next step for the bill is a vote by the full house. It will then be considered by The Texas Senate, and if passed, will require final approval by Texas Governor Greg Abbott. It is anticipated that it would take full effect in September 2021, if approved and signed into law.

"This positive step in the legislative process is very encouraging and we hope the next step will also be a positive stride forwards in providing significantly improved access to scalp cooling during chemotherapy for many patient groups in Texas, where the company now has over 40 locations offering the Paxman Scalp Cooler," commented Richard Paxman, CEO of Paxman.

Contacts

Richard Paxman, CEO
Tel: +44 7968 020641
Email: richard@paxmanscalpcooling.com
www.paxman.se

About Us

The Paxman Scalp Cooling System has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The concept behind the system came when the mother of four, Sue Paxman, experienced first-hand the trauma of chemotherapy-induced hair loss. With close to 3,500 systems delivered in to hospitals, clinics and treatment centres around the world, PAXMAN is the leading supplier of Scalp Cooling technology. PAXMAN's scalp-cooling cap is made from lightweight, biocompatible silicone that is soft and flexible, providing a snug yet comfortable fit during treatment. PAXMAN AB (publ) has its headquarters in Karlshamn (Sweden), with subsidiaries in Huddersfield (UK) and Houston, Texas (US).

The PAXMAN share is listed on Nasdaq First North Growth Market. FNCA Sweden AB is the company's Certified Adviser and can be contacted via info@fnca.se and +46 (0)8 528 003 99.

Attachments

[Bill for mandatory coverage of scalp cooling passed by Texas House committee](#)